Crinetics Pharmaceuticals (CRNX) Operating Leases (2019 - 2026)

Crinetics Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $41.3 million for Q1 2026.

• In Q1 2026, Operating Leases fell 5.96% year-over-year to $41.3 million; the TTM figure through Mar 2026 stood at $41.3 million (down 5.96% YoY), while the FY2025 annual figure was $42.1 million, down 5.65% from the prior year.
• Operating Leases for Q1 2026 stood at $41.3 million, down from $42.1 million in the prior quarter.
• The five-year high for Operating Leases was $48.2 million in Q3 2023, with the low at $1.5 million in Q2 2023.
• The 5-year median for Operating Leases is $42.7 million (2025), against an average of $29.7 million.
• The sharpest annual moves came in 2023 and 2024: Operating Leases plunged 43.24% in 2023, then jumped 3050.62% in 2024.
• Crinetics Pharmaceuticals' Operating Leases stood at $2.0 million in 2022, then surged by 2249.56% to $47.6 million in 2023, then decreased by 6.28% to $44.6 million in 2024, then slipped by 5.65% to $42.1 million in 2025, then fell by 1.74% to $41.3 million in 2026.
• Business Quant data shows CRNX's Operating Leases at $41.3 million in Q1 2026, $42.1 million in Q4 2025, and $42.7 million in Q3 2025.